{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T20:26:09Z","timestamp":1790108769696,"version":"4.0.1"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T00:00:00Z","timestamp":1733270400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Infection, Genetics and Evolution"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.meegid.2024.105700","type":"journal-article","created":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T16:37:13Z","timestamp":1733762233000},"page":"105700","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Prevalence and drug resistance analysis of hepatitis C virus genotypes in Heilongjiang, China"],"prefix":"10.1016","volume":"127","author":[{"given":"Bo","family":"Du","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Le","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingku","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongzheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuyun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.meegid.2024.105700_bb0005","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01269-19","article-title":"Interplay of amino acid residues at positions 28 and 31 in NS5A defines resistance pathways in HCV GT2","volume":"63","author":"Asante-Appiah","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.meegid.2024.105700_bb0010","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/hepr.13292","article-title":"Efficacy and safety of ombitasvir\/paritaprevir\/ritonavir and ribavirin for chronic hepatitis patients infected with genotype 2a in Japan","volume":"49","author":"Atsukawa","year":"2019","journal-title":"Hepatol. Res."},{"key":"10.1016\/j.meegid.2024.105700_bb0015","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1111\/add.14643","article-title":"Understanding and using time series analyses in addiction research","volume":"114","author":"Beard","year":"2019","journal-title":"Addiction"},{"key":"10.1016\/j.meegid.2024.105700_bb0020","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1093\/infdis\/jiy401","article-title":"Identification of a novel hepatitis C virus genotype from Punjab, India: expanding classification of hepatitis C virus into 8 genotypes","volume":"218","author":"Borgia","year":"2018","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.meegid.2024.105700_bb0025","doi-asserted-by":"crossref","DOI":"10.3390\/v10050223","article-title":"Characterization of NS5A and NS5B resistance-associated substitutions from genotype 1 hepatitis C virus infected patients in a Portuguese cohort","volume":"10","author":"Brand\u00e3o","year":"2018","journal-title":"Viruses"},{"key":"10.1016\/j.meegid.2024.105700_bb0030","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1056\/NEJMra2033539","article-title":"Extrahepatic manifestations of chronic HCV infection","volume":"384","author":"Cacoub","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.meegid.2024.105700_bb0035","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.coviro.2018.10.005","article-title":"Viral resistance in HCV infection","volume":"32","author":"Ceccherini-Silberstein","year":"2018","journal-title":"Curr. Opin. Virol."},{"issue":"7","key":"10.1016\/j.meegid.2024.105700_bb0045","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1004035","article-title":"Global influenza surveillance systems to detect the spread of influenza-negative influenza-like illness during the COVID-19 pandemic: time series outlier analyses from 2015-2020","volume":"19","author":"Cobb","year":"2022","journal-title":"PLoS Med."},{"key":"10.1016\/j.meegid.2024.105700_bb0050","author":"DCPPC"},{"key":"10.1016\/j.meegid.2024.105700_bb0055","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jhep.2022.08.016","article-title":"Long-term persistence of HCV resistance-associated substitutions after DAA treatment failure","volume":"78","author":"Dietz","year":"2023","journal-title":"J. Hepatol."},{"key":"10.1016\/j.meegid.2024.105700_bb0060","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/jmv.25311","article-title":"The nationwide distribution and trends of hepatitis C virus genotypes in mainland China","volume":"91","author":"Du","year":"2019","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.meegid.2024.105700_bb0065","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.virs.2022.07.005","article-title":"HCV 6a was expanding and became the predominant subtype among blood donors between 2004 and 2019 in Guangdong, China","volume":"37","author":"Du","year":"2022","journal-title":"Virol. Sin."},{"key":"10.1016\/j.meegid.2024.105700_bb0070","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1111\/liv.15150","article-title":"Road to elimination of HCV: clinical challenges in HCV management","volume":"42","author":"Hayes","year":"2022","journal-title":"Liver Int."},{"issue":"3","key":"10.1016\/j.meegid.2024.105700_bb0075","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1007\/s12072-015-9624-2","article-title":"HCV NS5A resistance-associated variants in a group of real-world Japanese patients chronically infected with HCV genotype 1b","volume":"9","author":"Hirotsu","year":"2015","journal-title":"Hepatol. Int."},{"key":"10.1016\/j.meegid.2024.105700_bb0080","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1089\/mdr.2018.0360","article-title":"Comparison of naturally occurring resistance-associated substitutions between 2008 and 2016 in Chinese patients with chronic hepatitis C virus infection","volume":"25","author":"Huang","year":"2019","journal-title":"Microbial. Drug Resistance (Larchmont, N.Y.)"},{"key":"10.1016\/j.meegid.2024.105700_bb0085","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2022.860171","article-title":"Factors associated with newly HIV infection and transmitted drug resistance among men who have sex with men in Harbin, P.R. China","volume":"10","author":"Hui","year":"2022","journal-title":"Front. Public Health"},{"key":"10.1016\/j.meegid.2024.105700_bb0090","author":"ICTV"},{"key":"10.1016\/j.meegid.2024.105700_bb0095","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1111\/hepr.12898","article-title":"Clinical evaluation of sofosbuvir\/ledipasvir in patients with chronic hepatitis C genotype 1 with and without prior daclatasvir\/asunaprevir therapy","volume":"47","author":"Iio","year":"2017","journal-title":"Hepatol. Res."},{"key":"10.1016\/j.meegid.2024.105700_bb0100","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ijid.2021.09.041","article-title":"Prevalence of resistance-associated substitutions and phylogenetic analysis of hepatitis C virus infection in Russia","volume":"113","author":"Isakov","year":"2021","journal-title":"Int. J. Infect. Dis."},{"key":"10.1016\/j.meegid.2024.105700_bb0105","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1111\/hepr.12685","article-title":"Prevalence and characteristics of naturally occurring sofosbuvir resistance-associated variants in patients with hepatitis C virus genotype 1b infection","volume":"46","author":"Ito","year":"2016","journal-title":"Hepatol. Res."},{"key":"10.1016\/j.meegid.2024.105700_bb0110","doi-asserted-by":"crossref","first-page":"1092936","DOI":"10.3389\/fcimb.2023.1092936","article-title":"The distribution of hepatitis C viral genotypes shifted among chronic hepatitis C patients in Yunnan, China, between 2008-2018","volume":"13","author":"Jia","year":"2023","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"10.1016\/j.meegid.2024.105700_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104871","article-title":"Molecular characterization of hepatitis C virus for subtype determination and resistance-associated substitutions detection among Chinese voluntary blood donors","volume":"181","author":"Jiang","year":"2020","journal-title":"Antiviral Res."},{"key":"10.1016\/j.meegid.2024.105700_bb0120","doi-asserted-by":"crossref","first-page":"8910","DOI":"10.3748\/wjg.v22.i40.8910","article-title":"Polymorphisms and resistance mutations of hepatitis C virus on sequences in the European hepatitis C virus database","volume":"22","author":"Kliemann","year":"2016","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.meegid.2024.105700_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.epidem.2021.100442","article-title":"Estimated prevalence of undiagnosed HCV infected individuals in Italy: a mathematical model by route of transmission and fibrosis progression","volume":"34","author":"Kondili","year":"2021","journal-title":"Epidemics"},{"key":"10.1016\/j.meegid.2024.105700_bb0130","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1128\/AAC.02606-15","article-title":"Analysis of hepatitis C virus genotype 1b resistance variants in Japanese patients treated with Paritaprevir-ritonavir and Ombitasvir","volume":"60","author":"Krishnan","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.meegid.2024.105700_bb0135","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1128\/JVI.01360-09","article-title":"Identification of hepatitis C virus NS5A inhibitors","volume":"84","author":"Lemm","year":"2010","journal-title":"J. Virol."},{"key":"10.1016\/j.meegid.2024.105700_bb0140","doi-asserted-by":"crossref","first-page":"3795","DOI":"10.1128\/AAC.00146-11","article-title":"Discovery of potent hepatitis C virus NS5A inhibitors with dimeric structures","volume":"55","author":"Lemm","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.meegid.2024.105700_bb0145","doi-asserted-by":"crossref","first-page":"377","DOI":"10.2147\/IDR.S146595","article-title":"Prevalence of hepatitis C virus-resistant association substitutions to direct-acting antiviral agents in treatment-na\u00efve hepatitis C genotype 1b-infected patients in western China","volume":"10","author":"Li","year":"2017","journal-title":"Infect. Drug Resist."},{"key":"10.1016\/j.meegid.2024.105700_bb0150","doi-asserted-by":"crossref","first-page":"623","DOI":"10.3350\/cmh.2022.0349","article-title":"Acute hepatitis C virus infection: clinical update and remaining challenges","volume":"29","author":"Liu","year":"2023","journal-title":"Clin. Mol. Hepatol."},{"key":"10.1016\/j.meegid.2024.105700_bb0155","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1016\/j.cgh.2019.10.046","article-title":"World-wide prevalence of substitutions in HCV genome associated with resistance to direct-acting antiviral agents","volume":"19","author":"Liu","year":"2021","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"1","key":"10.1016\/j.meegid.2024.105700_bb0160","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1186\/s12889-022-14642-3","article-title":"Comparison of ARIMA model, DNN model and LSTM model in predicting disease burden of occupational pneumoconiosis in Tianjin, China","volume":"22","author":"Lou","year":"2022","journal-title":"BMC Public Health"},{"key":"10.1016\/j.meegid.2024.105700_bb0165","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/s41575-022-00608-8","article-title":"Breakthroughs in hepatitis C research: from discovery to cure","volume":"19","author":"Manns","year":"2022","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.meegid.2024.105700_bb0170","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S0140-6736(23)01320-X","article-title":"Hepatitis C","volume":"402","author":"Martinello","year":"2023","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.meegid.2024.105700_bb0175","doi-asserted-by":"crossref","DOI":"10.3390\/v13010041","article-title":"Therapy implications of hepatitis C virus genetic diversity","volume":"13","author":"Martinez","year":"2020","journal-title":"Viruses"},{"key":"10.1016\/j.meegid.2024.105700_bb0180","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1186\/1743-422X-10-355","article-title":"Naturally occurring resistance mutations to inhibitors of HCV NS5A region and NS5B polymerase in DAA treatment-na\u00efve patients","volume":"10","author":"Paolucci","year":"2013","journal-title":"Virol. J."},{"key":"10.1016\/j.meegid.2024.105700_bb0185","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1128\/AAC.02776-15","article-title":"Comprehensive screening for naturally occurring hepatitis C virus resistance to direct-acting antivirals in the NS3, NS5A, and NS5B genes in worldwide isolates of viral genotypes 1 to 6","volume":"60","author":"Pati\u00f1o-Galindo","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.meegid.2024.105700_bb0190","article-title":"Epidemiology and genotype distribution of hepatitis C virus in Russia","volume":"11","author":"Pimenov","year":"2022","journal-title":"Pathogens (Basel, Switzerland)"},{"issue":"3","key":"10.1016\/j.meegid.2024.105700_bb0195","doi-asserted-by":"crossref","first-page":"e01888","DOI":"10.1128\/AAC.01888-19","article-title":"Cell culture studies of the efficacy and barrier to resistance of Sofosbuvir-Velpatasvir and Glecaprevir-Pibrentasvir against hepatitis C virus genotypes 2a, 2b, and 2c","volume":"64","author":"Ramirez","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.meegid.2024.105700_bb0200","doi-asserted-by":"crossref","DOI":"10.3390\/microorganisms12061035","article-title":"Contemporary insights into hepatitis C virus: a comprehensive review","volume":"12","author":"Sallam","year":"2024","journal-title":"Microorganisms"},{"key":"10.1016\/j.meegid.2024.105700_bb0205","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.jhep.2021.04.045","article-title":"Non-epidemic HCV genotypes in low- and middle-income countries and the risk of resistance to current direct-acting antiviral regimens","volume":"75","author":"Shah","year":"2021","journal-title":"J. Hepatol."},{"key":"10.1016\/j.meegid.2024.105700_bb0210","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1111\/apt.15633","article-title":"Systematic review with meta-analysis: impact of baseline resistance-associated substitutions on the efficacy of glecaprevir\/pibrentasvir among chronic hepatitis C patients","volume":"51","author":"Singh","year":"2020","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.meegid.2024.105700_bb0215","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.drup.2018.01.004","article-title":"Hepatitis C virus drug resistance associated substitutions and their clinical relevance: update 2018","volume":"37","author":"Sorbo","year":"2018","journal-title":"Drug Resist. Updates"},{"key":"10.1016\/j.meegid.2024.105700_bb0220","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1111\/hepr.13401","article-title":"Effects of resistance-associated variants in genotype 2 hepatitis C virus on viral replication and susceptibility to antihepatitis C virus drugs","volume":"49","author":"Suda","year":"2019","journal-title":"Hepatol. Res."},{"key":"10.1016\/j.meegid.2024.105700_bb0225","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s40249-023-01106-y","article-title":"Molecular epidemiology of hepatitis C virus genotypes in different geographical regions of Chinese mainland and a phylogenetic analysis","volume":"12","author":"Tang","year":"2023","journal-title":"Infect. Dis. Poverty"},{"key":"10.1016\/j.meegid.2024.105700_bb0230","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1093\/humrep\/deae008","article-title":"The epidemiology of pregnancy loss: global burden, variable risk factors, and predictions","volume":"39","author":"Tong","year":"2024","journal-title":"Hum. Reprod."},{"key":"10.1016\/j.meegid.2024.105700_bb0235","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1136\/gutjnl-2024-332177","article-title":"'Unusual' HCV genotype subtypes: origin, distribution, sensitivity to direct-acting antiviral drugs and behaviour on antiviral treatment and retreatment","volume":"73","author":"Vo-Quang","year":"2024","journal-title":"Gut"},{"key":"10.1016\/j.meegid.2024.105700_bb0240","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1007\/s00705-019-04260-7","article-title":"Hepatitis C virus 3b strains in injection drug users in Guangdong Province, China, may have originated in Yunnan Province","volume":"164","author":"Wang","year":"2019","journal-title":"Arch. Virol."},{"key":"10.1016\/j.meegid.2024.105700_bb0245","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.4103\/0366-6999.166038","article-title":"Direct-acting antiviral agents resistance-associated polymorphisms in Chinese treatment-na\u00efve patients infected with genotype 1b hepatitis C virus","volume":"128","author":"Wang","year":"2015","journal-title":"Chin. Med. J. (Engl)"},{"key":"10.1016\/j.meegid.2024.105700_bb0250","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.antiviral.2018.08.001","article-title":"HCV phylogenetic signature and prevalence of pretreatment NS5A and NS5B NI-resistance associated substitutions in HCV-infected patients in mainland China","volume":"158","author":"Wei","year":"2018","journal-title":"Antiviral Res."},{"key":"10.1016\/j.meegid.2024.105700_bb0255","author":"WHO"},{"key":"10.1016\/j.meegid.2024.105700_bb0260","author":"WHO"},{"key":"10.1016\/j.meegid.2024.105700_bib281","doi-asserted-by":"crossref","first-page":"105653","DOI":"10.1016\/j.meegid.2024.105653","article-title":"Hepatitis C virus subtype distribution and resistance-associated substitutions in high-risk population groups in Guangdong Province, China","volume":"123","author":"Xie","year":"2024","journal-title":"Infect Genet Evol"},{"key":"10.1016\/j.meegid.2024.105700_bb0265","doi-asserted-by":"crossref","DOI":"10.3390\/v14071514","article-title":"The transmission route and selection pressure in HCV subtype 3a and 3b Chinese infections: evolutionary kinetics and selective force analysis","volume":"14","author":"Xu","year":"2022","journal-title":"Viruses"},{"key":"10.1016\/j.meegid.2024.105700_bb0270","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s12985-017-0710-z","article-title":"Hepatitis C virus in mainland China with an emphasis on genotype and subtype distribution","volume":"14","author":"Zhang","year":"2017","journal-title":"Virol. J."},{"key":"10.1016\/j.meegid.2024.105700_bb0275","article-title":"Feasibility of hepatitis C elimination in China: from epidemiology, natural history, and intervention perspectives","volume":"13","author":"Zhao","year":"2022","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.meegid.2024.105700_bb0280","doi-asserted-by":"crossref","DOI":"10.1016\/j.ypmed.2023.107749","article-title":"Trends and prediction in the incidence rate of hepatitis C in Shandong Province in China from 2004 to 2030","volume":"177","author":"Zheng","year":"2023","journal-title":"Prev. Med."}],"container-title":["Infection, Genetics and Evolution"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567134824001527?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567134824001527?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T16:50:13Z","timestamp":1736527813000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567134824001527"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":56,"alternative-id":["S1567134824001527"],"URL":"https:\/\/doi.org\/10.1016\/j.meegid.2024.105700","relation":{},"ISSN":["1567-1348"],"issn-type":[{"value":"1567-1348","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prevalence and drug resistance analysis of hepatitis C virus genotypes in Heilongjiang, China","name":"articletitle","label":"Article Title"},{"value":"Infection, Genetics and Evolution","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.meegid.2024.105700","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105700"}}